Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Table 3

Pooled results of acquired T790M detection rates in the and TKI alone groups.

Study	Treatment arm	Test samples	Test methods	Test cases ()	Cases of T790M ()	T790M rate	Pooled T790M rate	RR/P value (A + T vs. TKI)
NEJ026 [13, 25]		Plasma	(PNA-LNA) PCR clamp	42	8	19%	30.4% (95% CI: 21.7–39.1%) vs. TKI 34.6% (95% CI: 27.3–42%)	(95% CI: 0.668–1.358),
	Erl	Plasma	(PNA-LNA) PCR clamp	45	11	20.8%
		Tissue	(PNA-LNA) PCR clamp	7	4	57.1%
	Erl	Tissue	(PNA-LNA) PCR clamp	9	4	44.4%
RELAY [15]		Plasma	NGS-360	44	19	43%
	Erl	Plasma	NGS-360	75	35	47%
CTONG1509 [14]		Tissue	NGS-448	6	2	33%
	Erl	Tissue	NGS-448	12	5	42%

Bev: bevacizumab; Erl: erlotinib; Ram: ramucirumab; NGS: next-generation sequencing; RR: relative risk ratios; TKI: tyrosine kinase inhibitor; : angiogenic inhibitors combined with TKI; PNA-LNA PCR clamp: peptide nucleic acid locked nucleic acid polymerase chain reaction clamp.